🔍

INDRAMEDCO - Indrapr.Medical

📊 NSE: INDRAMEDCO 🏢 Healthcare 📅 Last Updated: 12/14/2025 8:03

📢 Recent Corporate Announcements

Indraprastha Medical Seeks Shareholder Approval for Appointment of 4 Independent Directors

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 18 Feb 2026, 04:49 PM

Indraprastha Medical Corporation Limited has issued a postal ballot notice to seek shareholder approval for the appointment and re-appointment of four Independent Directors. The company is proposing second five-year terms for Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli, alongside the new appointment of Mr. Harsh Pati Singhania. Notably, special resolutions are required for Mr. Singhal and Ms. Rai as they have exceeded the age of 75. The e-voting period is scheduled from February 19, 2026, to March 20, 2026, with results to be declared shortly thereafter.

Proposed re-appointment of 3 Independent Directors for a second 5-year term starting in 2026.
New appointment of Mr. Harsh Pati Singhania as an Independent Director.
Special resolutions required for 2 directors (Mr. Salil Singhal and Ms. Vineeta Rai) who are over 75 years old.
E-voting period set for 30 days, from February 19, 2026, to March 20, 2026.

💡 Investors should monitor the voting results to ensure board stability and continuity. No immediate action is required as these are routine governance matters.

Indraprastha Medical Approves Q3 Results; Appoints Harsh Pati Singhania to Board for 5-Year Term

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 09 Feb 2026, 11:52 AM

Indraprastha Medical Corporation (Indraprastha Apollo) has approved its financial results for the quarter and nine months ended December 31, 2025. A significant update was provided regarding the ongoing land lease litigation for the Sarita Vihar hospital, with the Delhi Government filing a new affidavit in the Supreme Court. The company also announced major board changes, including the appointment of high-profile industrialist Harsh Pati Singhania as an Independent Director. Additionally, three existing independent directors were re-appointed for five-year terms, ensuring continuity in governance.

Approved un-audited financial results for the quarter and nine-month period ended December 31, 2025.
Noted a new affidavit filed by the Delhi Government in the Supreme Court regarding the Sarita Vihar hospital land lease matter.
Appointed Mr. Harsh Pati Singhania (CMD of JK Paper) as an Independent Director for a 5-year term until February 2031.
Re-appointed three Independent Directors (Salil Singhal, Vineeta Rai, and Madhumita Ganguli) for second 5-year terms.
The board meeting concluded on February 3, 2026, after a session lasting over two hours.

💡 Investors should closely monitor the Supreme Court proceedings regarding the land lease, as this remains a critical legal overhang for the company's primary asset. The addition of experienced industrial leadership to the board is a positive development for corporate governance.

Indraprastha Medical Appoints Harsh Pati Singhania to Board; Updates on Land Lease Legal Case

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 03 Feb 2026, 06:56 PM

Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) has approved its Q3 FY26 financial results and announced significant board changes. Mr. Harsh Pati Singhania, CMD of JK Paper, has been appointed as an Independent Director for a five-year term effective February 3, 2026. The company also re-appointed three other Independent Directors, including Mr. Salil Singhal and Ms. Madhumita Ganguli, for second five-year terms. Additionally, the company is reviewing a new affidavit filed by the Delhi Government in the Supreme Court regarding the ongoing land lease and free patient treatment matter.

Approved unaudited financial results for the quarter and nine months ended December 31, 2025
Appointed Mr. Harsh Pati Singhania as Independent Director for a 5-year term ending February 2031
Re-appointed three Independent Directors for 5-year terms to ensure board continuity
Noted a new affidavit from the Govt. of NCT of Delhi regarding the Sarita Vihar hospital land lease litigation
The ongoing 'Free Patient Matter' remains under consideration by the Hon'ble Supreme Court of India

💡 Investors should closely monitor the Supreme Court proceedings regarding the land lease and free patient matter as it represents a significant operational risk. The addition of high-profile industrial leaders to the board is a positive signal for corporate governance.

Indraprastha Medical Appoints Harsh Pati Singhania to Board; Approves Q3 FY26 Results

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 03 Feb 2026, 06:55 PM

Indraprastha Medical Corporation (Indraprastha Apollo) has approved its Q3 FY26 financial results and announced a significant board refresh. Mr. Harsh Pati Singhania, CMD of JK Paper, has been appointed as an Independent Director for a five-year term. Additionally, three existing independent directors, including Ms. Vineeta Rai and Mr. Salil Singhal, were re-appointed for second five-year terms. The company also disclosed a legal update regarding an affidavit filed by the Delhi Government in the ongoing Supreme Court case concerning the hospital's land lease and free patient treatment obligations.

Appointment of Mr. Harsh Pati Singhania as Non-Executive Independent Director for a 5-year term (2026-2031).
Re-appointment of Ms. Vineeta Rai and Mr. Salil Singhal for second 5-year terms effective February 8, 2026.
Approval of un-audited financial results for the quarter and nine months ended December 31, 2025.
Ongoing legal monitoring of the Supreme Court case (SLP 29482/2009) regarding the hospital's land lease in Sarita Vihar.

💡 The addition of high-profile industrial leadership to the board is a positive for governance, but investors should primarily focus on the upcoming Q3 earnings details and the eventual Supreme Court ruling on the land lease matter.

Indraprastha Medical Approves Q3 Results, Appoints Harsh Pati Singhania as Independent Director

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 03 Feb 2026, 06:53 PM

Indraprastha Medical Corporation Limited (Indraprastha Apollo) has approved its Q3 FY26 financial results and announced several key board appointments. Mr. Harsh Pati Singhania, CMD of JK Paper, joins as an Independent Director, while three others, including Mr. Salil Singhal, have been re-appointed for five-year terms. The company is also monitoring a legal update involving an affidavit filed by the Delhi Government in the Supreme Court regarding land lease and free patient treatment. These developments highlight a focus on governance and ongoing regulatory challenges.

Approved un-audited financial results for the quarter and nine months ended December 31, 2025
Appointed Mr. Harsh Pati Singhania (CMD, JK Paper) as Independent Director for a 5-year term starting Feb 2026
Re-appointed three Independent Directors, including Mr. Salil Singhal, for 5-year terms
Noted a new affidavit filed by the Delhi Government in the Supreme Court regarding the 'Free Patient Matter' and land lease

💡 Investors should review the detailed Q3 financial performance once published and closely monitor the Supreme Court proceedings regarding the land lease, as it represents a significant regulatory risk.

Indraprastha Medical Appoints Harsh Pati Singhania as Director; Re-appoints 3 Independent Directors

🟡 NEUTRAL ⭐ 7/10

MANAGEMENT 📅 03 Feb 2026, 06:52 PM

Indraprastha Medical Corporation has appointed Mr. Harsh Pati Singhania, CMD of JK Paper, as an Independent Director for a five-year term starting February 3, 2026. The board also approved the re-appointment of three other Independent Directors—Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli—for subsequent five-year terms. Additionally, the company noted a new affidavit filed by the Delhi Government regarding a long-standing legal matter (SLP 29482/2009) concerning free patient care and the hospital's land lease. While Q3 FY26 financial results were approved, specific figures were not disclosed in this announcement.

Appointment of Mr. Harsh Pati Singhania (CMD, JK Paper) as Independent Director for a 5-year term until Feb 2031.
Re-appointment of three Independent Directors for 5-year terms to ensure board continuity and governance.
Update on pending Supreme Court matter regarding land lease and free patient care obligations with the Delhi Government.
Approval of un-audited financial results for the quarter and nine months ended December 31, 2025.

💡 Investors should monitor the Supreme Court's decision on the land lease and free patient care matter as it remains a key regulatory risk. The induction of high-profile industry leaders to the board is a positive sign for long-term strategic oversight.

Indraprastha Medical Approves Q3 Results; Appoints Harsh Pati Singhania to Board

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 03 Feb 2026, 06:29 PM

Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) approved its Q3 FY26 financial results and addressed a critical legal update regarding its land lease. The company noted a new affidavit filed by the Delhi Government in the Supreme Court concerning the 'Free Patient Matter' and land lease terms. On the governance front, the board appointed Mr. Harsh Pati Singhania, CMD of JK Paper, as an Independent Director for five years. Additionally, three existing Independent Directors were re-appointed for second five-year terms, ensuring leadership continuity.

Approved un-audited financial results for the quarter and nine months ended December 31, 2025.
Appointed Mr. Harsh Pati Singhania as an Independent Director for a 5-year term effective February 3, 2026.
Re-appointed three Independent Directors (Salil Singhal, Vineeta Rai, and Madhumita Ganguli) for 5-year terms.
Noted a new affidavit from the Delhi Government in the ongoing Supreme Court case (SLP 29482/2009) regarding the hospital's land lease.

💡 Investors should closely monitor the Supreme Court's upcoming deliberations on the land lease and free patient matter, as this remains a significant regulatory overhang. The addition of high-profile industrial leadership to the board is a positive indicator for corporate governance.

Indraprastha Medical Corp Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 14 Jan 2026, 04:57 PM

Indraprastha Medical Corporation Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited, covers the quarter ended December 31, 2025. This filing confirms that share certificates received for dematerialization have been verified, mutilated, and cancelled. Such filings are standard administrative procedures for listed companies in India to maintain accurate electronic shareholding records.

Submission of compliance certificate for the quarter ended December 31, 2025.
Certificate issued by Registrar & Share Transfer Agent MUFG Intime India Private Limited.
Confirms adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
Verification and cancellation of physical share certificates processed during the quarter.

💡 No action is required as this is a routine regulatory filing. Investors should monitor the company's upcoming quarterly financial results for fundamental performance updates.

Indraprastha Medical Corp to Close Trading Window from Jan 1, 2026, for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 19 Dec 2025, 11:33 AM

Indraprastha Medical Corporation Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI insider trading regulations. This closure is preparatory to the consideration and approval of the unaudited financial results for the quarter and nine months ending December 31, 2025. The window will remain closed for all designated persons, including directors and employees, until 48 hours after the results are officially declared. The specific date for the board meeting to approve these results will be communicated in due course.

Trading window closure begins on January 1, 2026, for the Q3 and nine-month period ending December 31, 2025.
The restriction applies to all directors, designated employees, and insiders under SEBI (Prohibition of Insider Trading) Regulations.
The window will reopen 48 hours after the announcement of the unaudited financial results to the stock exchanges.
The board meeting date for financial result approval is yet to be scheduled and will be intimated later.

💡 This is a routine regulatory announcement with no direct impact on stock valuation. Investors should look out for the upcoming board meeting date to assess the company's Q3 performance.

View All INDRAMEDCO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total income from operations grew to INR 1,356.36 Cr in FY25 from INR 1,244.70 Cr in FY24, representing a YoY increase of 8.97%. Revenue per patient increased by 2% to INR 202,869, while revenue per bed day grew by 5% to INR 66,064.

Geographic Revenue Split

The company faces high geographic concentration with 90-95% of its revenues derived from the National Capital Region (NCR), specifically from its two primary hospital properties.

Profitability Margins

Net Profit Ratio improved to 12% in FY25 compared to 10% in FY24, a 200 bps increase. Profit before tax rose 30.2% YoY to INR 216.32 Cr from INR 166.11 Cr.

EBITDA Margin

OPBITDA margins were reported at 14.3% in 9M FY23, improving from 13.5% in FY22. The improvement is driven by better operating metrics and a higher share of international patients and elective surgeries.

Capital Expenditure

Capital expenditure for FY25 was INR 36.33 Cr, a significant reduction from the INR 69.39 Cr spent in FY24. This includes investments in property, plant, equipment, and intangible assets like software licenses.

Credit Rating & Borrowing

The company maintains a strong liquidity position with ~INR 350 Cr in free cash and liquid balances. It remains debt-free with minimal gearing, resulting in robust debt protection indicators.

⚙️ Operational Drivers

Raw Materials

Specific raw material names like medical consumables and pharmaceuticals are not individually listed, but 'rising material costs' are identified as a key performance risk. Inventory stood at a net change of INR 0.54 Cr for the year.

Key Suppliers

Not disclosed in available documents; however, the company follows a stringent buy-back policy with vendors for e-waste and old medical equipment.

Capacity Expansion

Current operations are concentrated in two properties in the NCR. While specific MT/MW metrics are not applicable, the company focused on increasing discharges to 64,423 (up 7% YoY) and out-patient volumes to 596,285 (up 7% YoY).

Raw Material Costs

Material costs are noted as a risk factor that could influence performance, though specific percentage of revenue is not explicitly broken down in the provided snippets.

Manufacturing Efficiency

Bed occupancy was reported at 69% in 9M FY23. Average length of stay (ALOS) improved (decreased) to 3.07 days in FY25 from 3.16 days in FY24, enhancing bed turnover efficiency.

📈 Strategic Growth

Expected Growth Rate

9-12%

Growth Strategy

Growth is targeted through clinical excellence, innovation, and operational efficiency. The company is focusing on high-margin elective surgical procedures and has implemented price revisions to boost Average Revenue Per Operating Bed (ARPOB).

Products & Services

Healthcare services including Oncology, Neurology, Cardiology, Nephrology, and elective surgical procedures, alongside outpatient consultations and diagnostic services.

Brand Portfolio

Indraprastha Apollo Hospitals, backed by the parent brand Apollo Hospitals Enterprise Limited (AHEL).

New Products/Services

Expansion of elective surgical procedures and specialized clinical service lines are expected to be the primary drivers for FY26 growth.

Market Expansion

The company is focused on strengthening its market leadership within the NCR through technological upgrades and clinical innovation.

Market Share & Ranking

The company is a leading healthcare player in the NCR region, leveraging the Apollo brand's national market leadership.

Strategic Alliances

Apollo Hospitals Enterprise Limited (AHEL) and its promoters hold a 25% stake in the company, providing significant operational, financial, and managerial linkages.

🌍 External Factors

Industry Trends

The healthcare industry is seeing a shift toward elective surgeries and specialized care (Oncology/Cardiology). There is a growing trend toward energy efficiency in hospital infrastructure and digital transformation in patient records.

Competitive Landscape

Operates in a 'heightened competition' environment in the NCR with multiple private and government healthcare providers.

Competitive Moat

The company's moat is built on the 'Apollo' brand equity, a 25% strategic stake by AHEL, and a dominant clinical reputation in the NCR. This is sustainable due to high switching costs for complex surgeries and established referral networks.

Macro Economic Sensitivity

Sensitive to changes in the political or economic landscape and tax regimes. Performance is also linked to the resumption and stability of international travel for medical tourism.

Consumer Behavior

Increased demand for elective surgical procedures and high-quality sustainable healthcare services.

Geopolitical Risks

International patient flow is subject to geopolitical stability and travel regulations, as evidenced by the significant revenue jump post-travel resumption.

⚖️ Regulatory & Governance

Industry Regulations

Subject to price control measures and standard compliance requirements for medical services. It maintains cost records as prescribed under Section 148(1) of the Companies Act.

Environmental Compliance

Investments made in energy-efficient HVAC, water pumps, and chillers. Stringent buy-back policies for e-waste and medical equipment are in place to manage hazardous waste.

Taxation Policy Impact

The company is regular in depositing undisputed statutory dues including Income Tax and GST. Current tax liabilities stood at zero as of March 31, 2025, compared to INR 0.58 Cr the previous year.

Legal Contingencies

The company has disclosed pending litigations in Note 30.B and 30.C of its financial statements. While specific values are not in the summary, the auditor notes these could impact the financial position.

⚠️ Risk Analysis

Key Uncertainties

Asset concentration risk is high as revenue is derived from only two properties. Regulatory interventions in pricing could impact earnings by 5-10% if aggressive caps are implemented.

Geographic Concentration Risk

90-95% of revenue is concentrated in the NCR, making the company vulnerable to regional policy changes or economic downturns.

Third Party Dependencies

Dependency on Apollo Hospitals Enterprise Limited (AHEL) for brand and managerial linkages, and on specialized vendors for medical equipment maintenance.